Answers are grounded in this paper and cite their sources.
Evaluation of preoperative liquid biopsy metrics shows potential for risk stratification in lung cancer, suggesting improved treatment selection.
High-risk NSCLC is still difficult to identify. No blood test is approved for routine risk stratification, and ctDNA assays remain constrained by sensitivity, workflow burden, and cost. Although we previously reported RFS and OS, which patients benefit most from biomarker-based selection—and whether this approach is informative in the adjuvant setting—remains unresolved. Therefore, we evaluated preoperative liquid biopsy–based nucleosome quantification as a pragmatic strategy to refine clinical risk stratification.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: